Fulgent Genetics Provides Update on Testing for Covid-19
End-to-end testing enables Fulgent to more efficiently manage the demand it is seeing for both its RT-PCR and next-generation sequencing tests for Covid-19.
Read MorePosted by | Apr 15, 2020 | Covid 19, Emerging & Zoonotic Diseases, Infectious Diseases |
End-to-end testing enables Fulgent to more efficiently manage the demand it is seeing for both its RT-PCR and next-generation sequencing tests for Covid-19.
Read MorePosted by | Apr 13, 2020 | Infectious Diseases, Sexually Transmitted Diseases |
The task force recommends against screening pregnant people for bacterial vaginosis if they are not at increased risk for preterm delivery.
Read MorePosted by | Apr 13, 2020 | Covid 19, Emerging & Zoonotic Diseases, Infectious Diseases |
Sema4 is processing samples in its clinical laboratory, which can analyze 6,000 covid-19 tests per week and return results within 24 to 48 hours.
Read MorePosted by Steve Halasey | Apr 13, 2020 | Compliance, Computing Systems, Information Technology, Lab Management, Middleware & Software |
AI-driven software can help labs expertly navigate the prior authorization landscape.
Read MorePosted by | Apr 13, 2020 | Covid 19, Emerging & Zoonotic Diseases, Infectious Diseases |
The shared goal is to deliver high-purity, recombinant proteins for the development of covid-19 diagnostics and vaccines.
Read More